Drugs / GP2
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05232916 | Aug 2022 → Dec 2026 expected | breast cancer | Greenwich LifeSciences, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GP2 | “500 mcg/mL GP2 and 125 mcg/mL GM-CSF” NCT05232916 ↗ |
| Modality | Peptide | “HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF)” NCT05232916 ↗ |